Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Table 4 F-CP levels of patients with T2DM at 3, 6, and 12 months after MSCs therapy

Follow-up (months)	Test for heterogeneity		Analysis model	Test for overall effect		WMD or SMD	95% CI
Follow-up (months)	I² (%)	P	Analysis model	Z	P	WMD or SMD	95% CI
3	29	0.24	Fixed	1.65	0.10	0.46	(−0.09, 1.01)
6	42	0.19	Fixed	2.94	0.003	0.85	(0.29, 1.42)
12	0	0.96	Fixed	2.18	0.03	0.62	(0.06, 1.17)

Abbreviations: F-CP fasting C-peptide, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference

ISSN: 1757-6512